In vitro, ImmTAC fused with a TCR that has increased affinity after CDRs mutation by biological display technology can mediate CD8+ T cells to show specific cell lysis to tumor cells with low antigen density [31, 116, 117]. This evidence concerns the gene CD8A and neoplasm.